<code id='BF1E555B0C'></code><style id='BF1E555B0C'></style>
    • <acronym id='BF1E555B0C'></acronym>
      <center id='BF1E555B0C'><center id='BF1E555B0C'><tfoot id='BF1E555B0C'></tfoot></center><abbr id='BF1E555B0C'><dir id='BF1E555B0C'><tfoot id='BF1E555B0C'></tfoot><noframes id='BF1E555B0C'>

    • <optgroup id='BF1E555B0C'><strike id='BF1E555B0C'><sup id='BF1E555B0C'></sup></strike><code id='BF1E555B0C'></code></optgroup>
        1. <b id='BF1E555B0C'><label id='BF1E555B0C'><select id='BF1E555B0C'><dt id='BF1E555B0C'><span id='BF1E555B0C'></span></dt></select></label></b><u id='BF1E555B0C'></u>
          <i id='BF1E555B0C'><strike id='BF1E555B0C'><tt id='BF1E555B0C'><pre id='BF1E555B0C'></pre></tt></strike></i>

          entertainment

          entertainment

          author:fashion    Page View:43718
          Silhouette of a medical staff, followed by another, running pushing a nursing bed. Two people talk next to the hurrying staff in the corridor — coverage from STAT
          Adobe

          There’s ample evidence that private equity buyouts in health care drive up costs. A new study shows quality declines, too.

          Hospitals acquired by private equity saw a 25% uptick in adverse events compared with controls, according to a new study released today in the Journal of the American Medical Association. The findings add to an accumulating body of literature underscoring the harm that occurs when financial investors take over health care providers — not only hospitals, but nursing homes, hospice care, and physician practices.

          advertisement

          Even after adjusting their findings to be more conservative, the researchers on the JAMA study found that all of the hospital-acquired conditions they studied increased three years after a private equity acquisition compared to control hospitals. Not all of the increases were statistically significant.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Listen: Biogen's messy board & Laronde's data problem
          Listen: Biogen's messy board & Laronde's data problem

          SammyKimballforSTATCanunicornssurvivewithoutdata?Didbiotechgetoveritsskis?AndwhatisgoingonatBiogen?W

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Biden targets hefty hospital 'facility fees' that often surprise patients

          AdobeAspartoftheBidenadministration’sbroadereffortstolowerhealthcarecosts,theWhiteHouseannouncednewg